Toxicity level of polyherbal product containing Physta® Tongkat Ali (Eurycoma longifolia) and SLP+® Kacip Fatimah (Labisia pumila) in rodent
-
1
Institute for Medical Research, Ministry of Health (Malasiya), Malaysia
Background
Capsule blend containing Physta® Tongkat Ali (TA) and SLP+® Kacip Fatimah (KF) extracts is proposed to improve general health and well-being. Both Eurycoma longifolia & Labisia pumila plants are found in Malaysia and traditionally used to improve blood circulation, promote general health, overcome fatigue, and increase body strength. We aimed to evaluate the no-observed-adverse effect level (NOAEL) of this polyherbal formulation.
Methods
The sub-acute 28-day study was conducted according to Organization for Economic Cooperation and Development principles of Good Laboratory Practice. Both gender Wistar rats served as a control group (received water) while the other three groups were given the polyherbal formulation (TA and KF) at doses 125, 500 and 2,000mg/kg body weight (BW) administered daily via oral gavage for 28 days, respectively. On day 29, blood sampling was done for hematological & biochemical analysis and the rats were sacrificed and the organs collected for histopathological examination.
Results
The general, detailed and functional clinical observations of the rats showed no signs of toxicity. There were no significant changes in BW, food & water intake, gross examination on the bodies & organs, and biochemical & hematological parameters (p>0.05). Histopathological examination of the organs also did not reveal any dose related toxicity. However, an early response to exogenous toxicity was found in a number of organ tissues of some rats in the treated groups.
Conclusion
This study shows the polyherbal formulation does not cause acute toxicity but was found to cause an early response of exogenous toxicity at the higher doses (not all treated rats) after 28 days of treatment. Therefore, the NOAEL for the formulation is suggested to be not more than 2,000 mg/kg/day. The early response to exogenous toxicity highly suggests for longer dosing duration study to be conducted to investigate any further toxicity effect of the formulation.
Acknowledgements
This study was registered under the Ministry of Health, Malaysia under project number NMRR-15-2436-24582 (JPP-IMR 15-003). We would like to thank the Director General of Health Malaysia for his permission to publish this abstract. The authors also would like to acknowledge those who had contribute directly or indirectly in this study accomplishment.
Keywords:
Toxicity,
Eurycoma longifolia,
Labisia pumila,
Physta®,
SLP+®
Conference:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019.
Presentation Type:
Poster Presentation
Topic:
Miscellaneous
Citation:
Teh
BP,
Ibnu Rasid
E,
Zolkifli
N,
Sastu@Zakaria
U,
Muhammad
A,
Jusoh
B,
Mohamed Yusoff
N,
Zulkapli
A,
Sia
JY and
Ahmad
N
(2019). Toxicity level of polyherbal product containing Physta® Tongkat Ali (Eurycoma longifolia) and SLP+® Kacip Fatimah (Labisia pumila) in rodent.
Front. Pharmacol.
Conference Abstract:
International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18)
“Seizing Opportunities and Addressing Challenges of Precision Medicine”.
doi: 10.3389/conf.fphar.2018.63.00054
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
16 Oct 2018;
Published Online:
17 Jan 2019.
*
Correspondence:
Ms. Bee P Teh, Institute for Medical Research, Ministry of Health (Malasiya), Kuala Lumpur, Malaysia, tehbp@imr.gov.my